The Role of Team-Based Care Involving Pharmacists to Improve Cardiovascular and Renal Outcomes

Overview

Journal Cardiorenal Med

Publisher Karger

Specialties Cardiology & Vascular Diseases
Endocrinology
Nephrology

Date 2013 Feb 6

PMID 23381091

Citations 12

Authors

Lauren Odum

Adam Whaley-Connell

Affiliations

Soon will be listed here.

Abstract

The number of patients with cardiovascular and kidney disease in the United States continues to grow as the population ages, increasing the demand on the health care system and its providers. Many patients develop chronic conditions in which optimization of care is labor intensive, specifically hypertension, hyperlipidemia, diabetes, heart failure, and chronic kidney disease. Therefore, innovative and collaborative approaches to health care are warranted. Several team-based health care models have evolved and are gaining popularity, including the Patient-Centered Medical Home (PCMH) and Medication Therapy Management (MTM). Team-based care is widely supported in the literature, demonstrating significant improvement in cardiovascular and renal outcomes. This article will review the premises of PCMH and MTM, review the evidence and roles for team-based care specific to cardiovascular and renal outcomes, and introduce fundamentals to implement collaborative practice focusing on pharmacist-provider teams.

Citing Articles

Patient, Caregiver, and Provider Perspectives on Improving Provider-Patient Interactions in Hemodialysis: A Qualitative Study.

Talson M, Ferreira da Silva P, Finlay J, Rossum K, Soroka K, McCormick M Can J Kidney Health Dis. 2025; 12:20543581241309986.

PMID: 39758856 PMC: 11696963. DOI: 10.1177/20543581241309986.

Solutions for Atrial Fibrillation Edvocacy (SAFE): Improving Awareness And Access To Afib Screening For Detection And Referral For Treatment.

Little J, Bonham A, Bluml B Innov Pharm. 2023; 14(2).

PMID: 38025178 PMC: 10653716. DOI: 10.24926/iip.v14i2.5477.

The Impact of Primary Care Practice Models on Indicators of Unplanned Health Care Utilization for Ontario Adults Newly Diagnosed With Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.

Sheng R, Tranmer J, Godfrey C, Rotter T J Prim Care Community Health. 2023; 14:21501319231201080.

PMID: 37740528 PMC: 10517618. DOI: 10.1177/21501319231201080.

Knowledge of cardiovascular disease risk factors, practice, and barriers of community pharmacists on cardiovascular disease prevention in North West Ethiopia.

Birarra M, Baye E, Tesfa W, Kifle Z Metabol Open. 2022; 16:100219.

PMID: 36466186 PMC: 9712979. DOI: 10.1016/j.metop.2022.100219.

The role of pharmacists in the renal multidisciplinary team at a tertiary hospital in South Africa: Strategies to increase participation of pharmacists.

Manyama T, Tshitake R, Moloto N Health SA. 2020; 25:1357.

PMID: 32934826 PMC: 7479385. DOI: 10.4102/hsag.v25i0.1357.

References

Collins C, Limone B, Scholle J, Coleman C . Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Res Clin Pract. 2010; 92(2):145-52. DOI: 10.1016/j.diabres.2010.09.023. View

Lloyd-Jones D, Adams R, Brown T, Carnethon M, Dai S, de Simone G . Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010; 121(7):948-54. DOI: 10.1161/CIRCULATIONAHA.109.192666. View

Joy M, DeHart R, Gilmartin C, Hachey D, Hudson J, Pruchnicki M . Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. Am J Kidney Dis. 2005; 45(6):1105-18. DOI: 10.1053/j.ajkd.2005.02.027. View

Pai A, Boyd A, Depczynski J, Chavez I, Khan N, Manley H . Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009; 29(12):1433-40. DOI: 10.1592/phco.29.12.1433. View

Bluml B . Definition of medication therapy management: development of professionwide consensus. J Am Pharm Assoc (2003). 2005; 45(5):566-72. DOI: 10.1331/1544345055001274. View

Bunting B, Smith B, Sutherland S . The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc (2003). 2008; 48(1):23-31. DOI: 10.1331/JAPhA.2008.07140. View

Koshman S, Charrois T, Simpson S, McAlister F, Tsuyuki R . Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008; 168(7):687-94. DOI: 10.1001/archinte.168.7.687. View

Xu J, Kochanek K, Murphy S, Tejada-Vera B . Deaths: final data for 2007. Natl Vital Stat Rep. 2014; 58(19):1-19. View

Friedman E, Friedman A . Payment for donor kidneys: pros and cons. Kidney Int. 2006; 69(6):960-2. DOI: 10.1038/sj.ki.5000262. View

10.

Leung W, So W, Tong P, Chan N, Chan J . Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005; 118(12):1414. DOI: 10.1016/j.amjmed.2005.07.050. View

11.

Bozovich M, Rubino C, Edmunds J . Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy. 2000; 20(11):1375-83. DOI: 10.1592/phco.20.17.1375.34895. View

12.

Santschi V, Chiolero A, Burnand B, Colosimo A, Paradis G . Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011; 171(16):1441-53. DOI: 10.1001/archinternmed.2011.399. View

13.

Machado M, Nassor N, Bajcar J, Guzzo G, Einarson T . Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008; 42(9):1195-207. DOI: 10.1345/aph.1K618. View

14.

Carter B, Bosworth H, Green B . The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich). 2012; 14(1):51-65. PMC: 3257828. DOI: 10.1111/j.1751-7176.2011.00542.x. View

15.

Machado M, Bajcar J, Guzzo G, Einarson T . Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007; 41(11):1770-81. DOI: 10.1345/aph.1K311. View

16.

McKenney J, Slining J, HENDERSON H, Devins D, Barr M . The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 1973; 48(5):1104-11. DOI: 10.1161/01.cir.48.5.1104. View

17.

Stemer G, Lemmens-Gruber R . Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011; 12:35. PMC: 3166893. DOI: 10.1186/1471-2369-12-35. View

18.

Machado M, Bajcar J, Guzzo G, Einarson T . Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007; 41(10):1569-82. DOI: 10.1345/aph.1K151. View

19.

Gattis W, Hasselblad V, Whellan D, OConnor C . Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999; 159(16):1939-45. DOI: 10.1001/archinte.159.16.1939. View

20.

Carter B, Rogers M, Daly J, Zheng S, James P . The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009; 169(19):1748-55. PMC: 2882164. DOI: 10.1001/archinternmed.2009.316. View